In this session, the leadership behind Hansa Biopharma, AlzeCure Pharma, and SAGA Diagnostics share what it actually takes to get major partnerships over the finish line. Drawing on their recent licensing and commercial agreements, they will talk through the practical reality of dealmaking: finding the right partners, handling grueling due diligence, negotiating terms you can live with, and navigating the global market from the Nordics.

Martin Jönsson, CEO, AlzeCure
Renée Lucander, CEO, Hansa Biopharma
Lao Saal, Founder, SAGA Diagnostics and Medical Director, DoMore Diagnostics

All moderated by: Anna Gran, Founder, Askel

In May 2025, we presented a roadmap for navigating the rising uncertainties of the new US administration. One year later, the map has been redrawn. In this follow-up keynote, Andreas Dirnagl moves beyond initial speculation to analyze the tangible economic consequences of the ”America First” doctrine.

He reviews the actual impact of trade barriers and policy shifts on the bottom line for Nordic life science companies. Which fears materialized, and what is the real cost of protectionism? Based on market data from the first 18 months of the administration, we discuss how successful companies are adapting their strategies to survive and thrive in this solidified ”New Normal.”

Women’s health is a far broader investment landscape than traditionally perceived. In this session, moderator Cecilia Hallström, PhD, sits down with Anesa Mulabecirovic, MD PhD MBA, manager of DNB Fund Women’s Health, the world’s first actively managed equity fund dedicated entirely to the sector.

Drawing on 15 years of clinical practice and fund management expertise, Anesa will share how DNB builds its investment universe from the biology up, spanning pharmaceuticals, diagnostics, and medtech across the lifespan, and what targeted capital means for the future of life science investing.